

WFS1 K800E — Wolframin

Lysine → Glutamate at position 800 in luminal domain. ClinVar Conflicting. AlphaMissense 0.778, $\Delta\Delta G$ -0.40. pLDDT 72 borderline. Same K800-D801 salt-bridge pair as D801G.

IDENTITY

Variant	K800E (p.Lysine800Glutamate)
DNA change	c.2398A>G
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000215400
Amino acid change	Lysine (K) → Glutamate (E) — positively-charged amine replaced by negatively-charged carboxylate. Charge reversal.

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 800	71.69 HIGH CONFIDENCE
Domain	C-terminal luminal domain (653-869)
Position context	C-terminal luminal domain · position 800 (pLDDT 72).
IDR flag	No — pLDDT well above 50 threshold

Position 800 sits adjacent to D801. Neighbors: ASP801 (2.5 Å — D801G Atlas card!), THR799 (2.5 Å), ASP797 (3.7 Å), VAL798 (4.3 Å). The wild-type K800-D801 salt bridge (referenced in D801G Atlas card) breaks when K800 becomes E800: now TWO adjacent glutamates (E800, D801) with no positive charge to stabilize. The local electrostatic environment is transformed. $\Delta\Delta G$ 0.40 + AM 0.778 confirm severe consequence.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

0.778am_class: **LPath** —
threshold > 0.564DYNAMUT2 $\Delta\Delta G$ **-0.4** kcal/molDestabilising · Job
177992463771

PLDDT (ALPHAFOLD)

71.69

high confidence

CLINICAL EVIDENCE

ClinVar classification

CONFLICTING CLASSIFICATIONS OF PATHOGENICITY

Review status

criteria provided, conflicting classifications

Last evaluated

2025/11/03 00:00

Inheritance

Not specified.

WFS1 variant landscape

K800E is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)

- (no specific conditions catalogued)

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G$ 2–4 → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

Category 3/4 — Most Druggable. $|\Delta\Delta G| = 0.40$. AlphaMissense 0.778 confirms severe consequence.

Mechanism: K800-D801 salt bridge broken by charge-flip at K800.
Therapeutic: same K800-D801 microregion as D801G.

K800E + D801G are sister variants at the salt-bridge pair. Two convergent variant targets at the same ionic contact.